U.S. Markets closed

RAMM Pharma Corp. (RAMMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.67200.0000 (0.00%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6720
Open0.6720
BidN/A x N/A
AskN/A x N/A
Day's Range0.6720 - 0.6720
52 Week Range0.3458 - 0.9235
Volume1,000
Avg. Volume0
Market Cap71.606M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    RAMM Pharma Announces Resignation of Director

    TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, announces that Mr. Sergio Martines has resigned from the board of directors of the Company. The Company wishes Mr. Martines success in his future endeavors. About RAMM Pharma Corp. RAMM is a leader in the field of cannabinoid pharmacology and product formulation for can

  • GlobeNewswire

    RAMM Pharma Corp. Announces Intention to Commence Normal Course Issuer Bid

    TORONTO, July 06, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), announces its intention to commence a normal course issuer bid (the “NCIB”), under which it may purchase up to 5% of the current number of issued and outstanding common shares of the Company (the “Common Shares”). The NCIB may commence on or about July 12, 2021 and shall expire on the 12-month anniversary of the effective date of the NCIB. All Common Shares

  • GlobeNewswire

    RAMM Pharma Completes Acquisition of Canapar Corp.

    TORONTO, June 15, 2021 (GLOBE NEWSWIRE) -- Further to its news releases dated May 12 and June 14, 2021, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, is pleased to announce that the Company has completed its previously announced acquisition of Canapar Corp. (“Canapar”). Pursuant to the terms of the acquisition, RAMM acquired of all the common shares of Canap